Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis

Inclusion Criteria: * Men and women between the ages of 18 and 75 inclusive * HDL cholesterol \>= 25 mg/dL in all subjects, and \<= 60 mg/dL in men and \<= 70 mg/dL in women * Women must be of non-childbearing potential. They must have been surgically sterilized at least 6 months prior to screening or be postmenopausal. Postmenopausal women must have no regular menstrual bleeding for at least 2 years prior to inclusion. * Subjects must be in good overall health. * Subjects must be able to comprehend and willing to provide a signed Institutional Regulatory Board (IRB) approved Informed Consent Form. * Subjects must be willing to comply with all study-related procedures. * Subjects must weigh at least 140 pounds to participate in the HDL kinetics Substudy. Exclusion Criteria: * Clinically-manifest cardiovascular disease, including coronary disease, cerebrovascular disease, or peripheral vascular disease * History of diabetes mellitus or fasting glucose \> 126 mg/dL at the screening visit * Presence of New York Heart Association (NYHA) Class III or IV chronic heart failure or unstable angina pectoris * History of any other endocrine disease * History of a non-skin malignancy within the previous 5 years * Anemia defined as hemoglobin less than 12 g/dL * Renal insufficiency as defined by creatinine ³ 1.3 mg/dl * Any major active rheumatologic, pulmonary, or dermatologic disease or inflammatory condition * Uncontrolled hypertension (Systolic \>160 mm Hg and/or Diastolic \>100 mmHg on two consecutive measurements * Use of warfarin, or any known coagulopathy and /or elevated Prothrombin time/Partial Thromboplastin Time (PT/PTT) \>1.5 x upper limit of normal (ULN) * Self-reported history of Human immunodeficiency virus (HIV) positive * Previous organ transplantation * Clinical evidence of liver disease or liver injury as indicated by abnormal liver function tests such as Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2x ULN, or self-reported history of positive for Hepatitis B or Hepatitis C * Any major surgical procedure that occurred within the previous 3 months of the screening visit * History of illicit drug abuse (\< 1 year) * Regular use of alcoholic beverages (\> 2 drinks/day) * Body mass index (BMI) \> 35 kg/m2 or \< 18.5 kg/m2 * Administration of an investigational drug within 6 weeks prior to the screening visit * Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study will be excluded. * Use of daily lipid-altering therapy prior to the initiation of study medication is exclusionary under the following circumstances (washout of non-statins is permitted): * Statins within 4 weeks * Niacin \> 250 mg/ day within 6 weeks: Advicor, Niaspan, Niacor, Simcor, Slo-Niacin, or supplemental niacin * Fibrates within 12 weeks: fenofibrate (Antara, Lofibra, Tricor, Triglide), gemfibrozil (Lopid), or clofibrate * Enterically active lipid-altering drugs within 4 weeks: colestipol (Colestid), cholestyramine (Questran), colesevelam (Welchol), ezetimibe (Zetia, Vytorin), orlistat (Xenical, Alli) * Red yeast rice * Fish oil \> 2 g/day within 4 weeks: Lovaza (née Omacor), numerous supplements * Altered dose of a selective estrogen receptor modulator (SERM) within 4 weeks * History of severe intolerance of niacin * Men who plan to conceive a child within 3 months of the conclusion of the study.